Clinical and Demographic Profile of Inflammatory Bowel Disease Patients in a Reference Center of São Paulo, Brazil

• Published in: Clinical and experimental gastroenterology 2021-01, Vol.14, p.91-102
• Main Authors: Gomes, Tarcia Nogueira Ferreira, de Azevedo, Fabio Silva, Argollo, Marjorie, Miszputen, Sender Jankiel, Ambrogini, Jr, Orlando
• Format: Article
• Language: English
• Subjects: Age; Crohn's disease; Developing countries; Education; Epidemiology; Family medical history; Gastroenterology; Gastrointestinal system; Independent sample; Industrial development; Inflammatory bowel disease; Laboratories; Medical records; Medical research; Medicine, Experimental; Normal distribution; Original Research; Quality of life; Ulcerative colitis
• ISSN: 1178-7023; 1178-7023
• DOI: 10.2147/CEG.S288688

Crohn's disease (CD) and ulcerative colitis (UC) are chronic inflammatory diseases of the gastrointestinal tract with an increasing incidence in developing countries. To report clinical and demographic data of CD and UC at a referral center for inflammatory bowel disease (IBD) in São Paulo. We conducted a retrospective cross-sectional study on adult patients with established IBD. Demographic and clinical data were obtained by medical records analysis from the IBD Outpatient Clinic of EPM-UNIFESP, from October 1997 to October 2017. Of 658 patients included, 355 had UC (54%) and 303 had CD (46%). UC was more prevalent in women than CD (219 [61.7%] vs 152 [50.2%], p=0.003). The median time between the onset of symptoms and diagnosis was 13 (5-38) months, with a longer duration for CD patients. CD mostly affected the ileocolonic location (47.9%). CD patients with stricture, fistula and/or perianal disease (213/303, 70.3%) were younger at diagnosis, had a longer disease duration, higher rates of corticosteroid, immunomodulatory, and biological therapy, hospitalization, and referral to surgery, compared to patients without complication. Extensive colitis was the most common extension of UC (50.6%), which was more frequently associated with younger age at diagnosis, hepatobiliary disease, increased need for hospitalization, higher use of immunomodulatory, and biologic therapy, compared to patients with less extensive disease. In the last 5 years, CD patients were more frequently on biologic and/or immunomodulatory (70.9%) therapy, and UC patients often received salicylates (78.1%) and immunomodulatory (28.1%) treatments. There was a consistent reduction in salicylate usage for CD in the last 5 years compared to the total period of follow-up. Despite the increasing incidence, we highlight the diagnostic delay and a more complicated CD and extensive UC in this cohort, reflecting a high need for immunomodulatory and biological treatment, hospitalization, and surgery.